patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_238550 | REC_0012201 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.4 | 63 | female | 0 | 49 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:59.914417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970978 | REC_0012202 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 10.9 | 70 | female | 1 | 25 | 6 | 0 | entrectinib 600 mg daily | 42 | false | MSI-H | 2026-03-15T05:35:59.914652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637582 | REC_0012203 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 19.6 | 68 | male | 0 | 15 | 6.7 | 1 | pembrolizumab 200 mg q3w | 18.1 | false | MSI-H | 2026-03-15T05:35:59.914888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381060 | REC_0012204 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.2 | 71 | female | 1 | 63 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.1 | false | MSS | 2026-03-15T05:35:59.915116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953955 | REC_0012205 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.5 | 59 | male | 1 | 47 | 6.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:59.915349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741256 | REC_0012206 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.3 | 83 | male | 1 | 61 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.1 | false | MSS | 2026-03-15T05:35:59.915579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551931 | REC_0012207 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12 | 56 | male | 1 | 2 | 6.4 | 3 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:59.915816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589179 | REC_0012208 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.5 | 55 | female | 0 | 12 | 6.3 | 6 | pembrolizumab 200 mg q3w | 16.6 | false | MSS | 2026-03-15T05:35:59.916191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855578 | REC_0012209 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.4 | 57 | female | 0 | 14 | 5.9 | 8 | entrectinib 600 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:59.916439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173399 | REC_0012210 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 36 | 12.5 | 75 | female | 1 | 19 | 4 | 4 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:35:59.916674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518160 | REC_0012211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 8.7 | 63 | male | 1 | 22 | 5.5 | 4 | alectinib 600 mg BID | 10.1 | true | MSS | 2026-03-15T05:35:59.916908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149366 | REC_0012212 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 2.7 | 59 | male | 0 | 6 | 4.3 | 1 | pembrolizumab 200 mg q3w | 28.4 | true | MSS | 2026-03-15T05:35:59.917140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799520 | REC_0012213 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9.2 | 62 | female | 0 | 13 | 5.4 | 6 | sotorasib 960 mg daily | 7 | false | MSS | 2026-03-15T05:35:59.917373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545191 | REC_0012214 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.1 | 71 | female | 1 | 6 | 7.3 | 4 | entrectinib 600 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.917600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529977 | REC_0012215 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.9 | 78 | female | 2 | 11 | 6.5 | 5 | entrectinib 600 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.917831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755718 | REC_0012216 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.5 | 71 | female | 2 | 31 | 5.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:35:59.918061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903536 | REC_0012217 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.5 | 58 | male | 1 | 2 | 8.7 | 2 | pembrolizumab 200 mg q3w | 8.7 | false | MSS | 2026-03-15T05:35:59.918301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881977 | REC_0012218 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 11.2 | 59 | male | 0 | 33 | 7.4 | 8 | pembrolizumab 200 mg q3w | 5.7 | true | MSS | 2026-03-15T05:35:59.918538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537000 | REC_0012219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.6 | 72 | female | 2 | 10 | 4.5 | 6 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:59.918770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994924 | REC_0012220 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.2 | 72 | female | 1 | 40 | 8.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:59.919001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751191 | REC_0012221 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.5 | 81 | male | 2 | 9 | 6.9 | 6 | osimertinib 80 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:35:59.919283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569197 | REC_0012222 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 20.9 | 61 | male | 0 | 10 | 4.9 | 1 | alectinib 600 mg BID | 28.7 | false | MSS | 2026-03-15T05:35:59.919522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184667 | REC_0012223 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.8 | 72 | female | 1 | 8 | 5 | 4 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.919762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669386 | REC_0012224 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 12.2 | 64 | female | 1 | 23 | 5.9 | 7 | osimertinib 80 mg daily | 5.7 | true | MSS | 2026-03-15T05:35:59.919997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413264 | REC_0012225 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 19.6 | 64 | male | 1 | 18 | 6.3 | 3 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:59.920258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121732 | REC_0012226 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 18 | 57 | female | 0 | 17 | 6.9 | 7 | alectinib 600 mg BID | 10.8 | false | MSI-H | 2026-03-15T05:35:59.920493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152567 | REC_0012227 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 15 | 66 | female | 1 | 16 | 5.7 | 6 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:35:59.920722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426376 | REC_0012228 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 36 | 7.6 | 77 | female | 2 | 11 | 6.6 | 7 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:35:59.920947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727826 | REC_0012229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.3 | 61 | female | 0 | 14 | 6.5 | 8 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:35:59.921183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887603 | REC_0012230 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 12 | 60 | male | 0 | 9 | 6.2 | 0 | osimertinib 80 mg daily | 34.1 | false | MSI-H | 2026-03-15T05:35:59.921417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868564 | REC_0012231 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 7.9 | 55 | female | 0 | 7 | 4.7 | 7 | pembrolizumab 200 mg q3w | 14.9 | true | MSS | 2026-03-15T05:35:59.921648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898424 | REC_0012232 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.5 | 69 | female | 0 | 61 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:59.921879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593969 | REC_0012233 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.7 | 74 | male | 1 | 50 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.1 | true | MSS | 2026-03-15T05:35:59.922117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721289 | REC_0012234 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 2.5 | 66 | female | 1 | 36 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.5 | false | MSS | 2026-03-15T05:35:59.922390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371643 | REC_0012235 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 63 | female | 1 | 38 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:59.922626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685976 | REC_0012236 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9.6 | 73 | female | 0 | 10 | 5.3 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:59.922861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210728 | REC_0012237 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.8 | 72 | female | 3 | 20 | 4.7 | 7 | entrectinib 600 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.923094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343178 | REC_0012238 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.7 | 68 | female | 0 | 15 | 3.9 | 2 | entrectinib 600 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:35:59.923327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196563 | REC_0012239 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 10.6 | 83 | female | 0 | 20 | 5.5 | 1 | entrectinib 600 mg daily | 25.2 | true | MSI-H | 2026-03-15T05:35:59.923561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191590 | REC_0012240 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.4 | 62 | male | 0 | 3 | 7.2 | 5 | sotorasib 960 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:59.923797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908983 | REC_0012241 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 9.2 | 63 | male | 1 | 68 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.7 | true | MSS | 2026-03-15T05:35:59.924027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351551 | REC_0012242 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.8 | 73 | female | 1 | 15 | 5.9 | 4 | pembrolizumab 200 mg q3w | 10.7 | true | MSS | 2026-03-15T05:35:59.924362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517048 | REC_0012243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.3 | 70 | male | 3 | 9 | 3.8 | 7 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:59.924605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413222 | REC_0012244 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 6.7 | 72 | female | 2 | 15 | 3.2 | 1 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.924832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248907 | REC_0012245 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.4 | 56 | male | 1 | 5 | 6 | 6 | sotorasib 960 mg daily | 10 | true | MSS | 2026-03-15T05:35:59.925073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224848 | REC_0012246 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.1 | 76 | male | 3 | 13 | 4.9 | 1 | alectinib 600 mg BID | 14.2 | false | MSS | 2026-03-15T05:35:59.925304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701720 | REC_0012247 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.5 | 68 | female | 0 | 38 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:59.925577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326277 | REC_0012248 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.6 | 59 | female | 1 | 17 | 5.5 | 5 | alectinib 600 mg BID | 9.7 | false | MSS | 2026-03-15T05:35:59.925817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678921 | REC_0012249 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 10.7 | 64 | male | 1 | 11 | 4.9 | 6 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:59.926052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795597 | REC_0012250 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 13.8 | 61 | female | 0 | 15 | 4.4 | 5 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:35:59.926286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978090 | REC_0012251 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 5.6 | 65 | male | 1 | 15 | 4.2 | 5 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.926517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454446 | REC_0012252 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.8 | 71 | female | 1 | 18 | 5.3 | 4 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.926751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685254 | REC_0012253 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12 | 56 | female | 0 | 17 | 5.8 | 1 | sotorasib 960 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:59.926986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243093 | REC_0012254 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 7.8 | 70 | female | 2 | 18 | 5.4 | 6 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:35:59.927214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989615 | REC_0012255 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.6 | 66 | male | 0 | 59 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.7 | false | MSS | 2026-03-15T05:35:59.927447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303141 | REC_0012256 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.5 | 68 | female | 0 | 23 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.1 | false | MSS | 2026-03-15T05:35:59.927673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617525 | REC_0012257 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.4 | 67 | female | 1 | 23 | 5.7 | 0 | pembrolizumab 200 mg q3w | 25.1 | true | MSS | 2026-03-15T05:35:59.927909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716900 | REC_0012258 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 7 | 58 | female | 0 | 13 | 4.5 | 2 | entrectinib 600 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:59.928207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280775 | REC_0012259 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6 | 70 | female | 3 | 42 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:35:59.928445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165524 | REC_0012260 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9.3 | 58 | male | 0 | 12 | 4.3 | 2 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:59.928731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621699 | REC_0012261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11.3 | 74 | female | 2 | 19 | 5.8 | 1 | osimertinib 80 mg daily | 29.7 | true | MSI-H | 2026-03-15T05:35:59.928968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406441 | REC_0012262 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.6 | 62 | male | 0 | 16 | 6.6 | 4 | entrectinib 600 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:59.929204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391926 | REC_0012263 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 3.3 | 58 | female | 0 | 10 | 4.8 | 3 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:35:59.929437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137956 | REC_0012264 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 26 | 9.1 | 81 | female | 1 | 21 | 6 | 0 | pembrolizumab 200 mg q3w | 50.8 | false | MSS | 2026-03-15T05:35:59.929663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244262 | REC_0012265 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.2 | 53 | male | 0 | 6 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.5 | false | MSS | 2026-03-15T05:35:59.929894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488032 | REC_0012266 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 9.2 | 73 | female | 1 | 56 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:35:59.930124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323842 | REC_0012267 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.7 | 72 | male | 1 | 24 | 4.2 | 1 | pembrolizumab 200 mg q3w | 18.6 | true | MSS | 2026-03-15T05:35:59.930355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576160 | REC_0012268 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 9.4 | 71 | female | 2 | 12 | 4 | 0 | osimertinib 80 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:59.930583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928642 | REC_0012269 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.7 | 69 | female | 1 | 16 | 4.9 | 3 | entrectinib 600 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:59.930811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168952 | REC_0012270 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 6.9 | 58 | male | 0 | 21 | 2 | 6 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:59.931042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755312 | REC_0012271 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.2 | 77 | female | 1 | 12 | 6.9 | 5 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:59.931273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899357 | REC_0012272 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11 | 70 | female | 1 | 23 | 7.7 | 1 | entrectinib 600 mg daily | 23.1 | false | MSI-H | 2026-03-15T05:35:59.931508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620822 | REC_0012273 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 12.5 | 82 | female | 1 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:59.931786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664401 | REC_0012274 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.9 | 57 | female | 1 | 17 | 5.1 | 4 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.932023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244660 | REC_0012275 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 9.8 | 80 | female | 2 | 23 | 3.1 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:59.932284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169340 | REC_0012276 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.5 | 65 | female | 0 | 20 | 4.5 | 2 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:59.932520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833341 | REC_0012277 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 17.3 | 56 | female | 0 | 11 | 5.9 | 6 | sotorasib 960 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:59.932755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396987 | REC_0012278 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 18 | 11.7 | 71 | female | 1 | 12 | 5.9 | 0 | alectinib 600 mg BID | 30.7 | false | MSS | 2026-03-15T05:35:59.932984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853915 | REC_0012279 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15 | 81 | male | 1 | 28 | 6 | 7 | alectinib 600 mg BID | 22.9 | true | MSS | 2026-03-15T05:35:59.933220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824497 | REC_0012280 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 16.6 | 70 | female | 1 | 23 | 3.9 | 2 | alectinib 600 mg BID | 23 | false | MSI-H | 2026-03-15T05:35:59.933449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494835 | REC_0012281 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14.8 | 65 | female | 1 | 6 | 6.4 | 4 | sotorasib 960 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:59.933686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809243 | REC_0012282 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.2 | 58 | female | 1 | 6 | 6.2 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.933915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492563 | REC_0012283 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.7 | 75 | female | 2 | 32 | 3.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:59.934144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361279 | REC_0012284 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.8 | 62 | female | 1 | 24 | 6.5 | 6 | sotorasib 960 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:59.934381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124494 | REC_0012285 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.3 | 64 | female | 0 | 50 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:59.934614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647935 | REC_0012286 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14.1 | 65 | female | 0 | 16 | 6.5 | 5 | osimertinib 80 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:59.934893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305122 | REC_0012287 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 18.5 | 51 | male | 0 | 5 | 6.4 | 2 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:35:59.935131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506365 | REC_0012288 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.2 | 69 | female | 1 | 44 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.4 | true | MSS | 2026-03-15T05:35:59.935361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878414 | REC_0012289 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.3 | 70 | female | 1 | 18 | 7.5 | 2 | alectinib 600 mg BID | 17.1 | true | MSS | 2026-03-15T05:35:59.935591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981635 | REC_0012290 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 13.3 | 64 | male | 1 | 20 | 6.1 | 5 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.935829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637015 | REC_0012291 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.9 | 68 | female | 1 | 20 | 5.6 | 5 | pembrolizumab 200 mg q3w | 13.1 | true | MSS | 2026-03-15T05:35:59.936059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167918 | REC_0012292 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.9 | 52 | female | 0 | 19 | 5.6 | 2 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:35:59.936416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933931 | REC_0012293 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.1 | 74 | female | 1 | 16 | 7.9 | 5 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:59.936657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442745 | REC_0012294 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 41 | 11.1 | 73 | female | 2 | 20 | 3.8 | 5 | pembrolizumab 200 mg q3w | 12.4 | true | MSI-H | 2026-03-15T05:35:59.936888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998420 | REC_0012295 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 17.4 | 86 | female | 1 | 14 | 6.6 | 4 | alectinib 600 mg BID | 9.3 | false | MSI-H | 2026-03-15T05:35:59.937124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886633 | REC_0012296 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6.5 | 77 | female | 1 | 20 | 6 | 2 | sotorasib 960 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:59.937352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906684 | REC_0012297 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 7.7 | 62 | male | 1 | 17 | 4.8 | 3 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:59.937584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870349 | REC_0012298 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.4 | 77 | female | 3 | 36 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.937810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168533 | REC_0012299 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 5.2 | 62 | male | 1 | 21 | 5 | 4 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:35:59.938087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483252 | REC_0012300 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.7 | 70 | female | 1 | 14 | 3 | 6 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.938316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.